SCHEMBL7514299

SCHEMBL7514299

FC(F)(F)c1nnnn1-c1ccc(OC2CC2)c(CNC2CCCNC2c2ccccc2)c1

nearest known ligand 0.84

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 19/20 0.84

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8135117 1.00 TACR1 (0.84) TACR1
SCHEMBL7554409 1.00 TACR1 (0.84) TACR1
Hydrochloric Acid SCHEMBL7552964 0.99 TACR1 (0.84) TACR1
Hydrochloric Acid SCHEMBL7552970 0.99 TACR1 (0.84) TACR1
SCHEMBL8197202 0.98 TACR1 (0.83) TACR1
SCHEMBL6577603 0.98 TACR1 (0.83) TACR1
Hydrochloric Acid SCHEMBL6581407 0.97 TACR1 (0.83) TACR1
SCHEMBL7523974 0.93 TACR1 (0.73) TACR1
Hydrochloric Acid SCHEMBL7560810 0.92 TACR1 (0.73) TACR1
Hydrochloric Acid SCHEMBL7560807 0.92 TACR1 (0.73) TACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020052504-A1 PIPERIDINE DERIVATIVES AND THEIR USE AS TACHYKININ ANTAGONISTS ELLIOTT MATTHEW JASON (GB) 2002-05-02 US claimed
US-20020052504-A1 PIPERIDINE DERIVATIVES AND THEIR USE AS TACHYKININ ANTAGONISTS ELLIOTT MATTHEW JASON (GB) 2002-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052504-A1 PIPERIDINE DERIVATIVES AND THEIR USE AS TACHYKININ ANTAGONISTS HTR1D, HTR1A, TRPV1 TACR1 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.